Huntington's Disease News and Research

Latest Huntington's Disease News and Research

How Huntington's disease proteins move from cell to cell

How Huntington's disease proteins move from cell to cell

Raptor reopens enrollment in DR Cysteamine Phase 3 trial to treat patients with nephropathic cystinosis

Raptor reopens enrollment in DR Cysteamine Phase 3 trial to treat patients with nephropathic cystinosis

Neuralstem updates progress of ongoing clinical trial of spinal cord stem cells in treatment of ALS

Neuralstem updates progress of ongoing clinical trial of spinal cord stem cells in treatment of ALS

Scientists discover new method for early diagnosis, treatment of plaque-related diseases

Scientists discover new method for early diagnosis, treatment of plaque-related diseases

FDA grants Neuralstem orphan drug designation for treatment of ALS with spinal cord stem cells

FDA grants Neuralstem orphan drug designation for treatment of ALS with spinal cord stem cells

CeNeRx announces FDA approval of CXB909 IND for neuroprotection and neurodegenerative disorders

CeNeRx announces FDA approval of CXB909 IND for neuroprotection and neurodegenerative disorders

USPTO issues patent for Metabolon's UHPLC/MSn-based analytical platform

USPTO issues patent for Metabolon's UHPLC/MSn-based analytical platform

AMRI fourth quarter total revenue increases 12% to $48.6 million

AMRI fourth quarter total revenue increases 12% to $48.6 million

Defective nucleoli linked to Parkinson's disease

Defective nucleoli linked to Parkinson's disease

UMMS, Lundbeck announce research collaboration to develop targeted therapy for HD

UMMS, Lundbeck announce research collaboration to develop targeted therapy for HD

Neuralstem ends litigation with ReNeuron

Neuralstem ends litigation with ReNeuron

UMMS, Lundbeck enter research collaboration to develop targeted therapy for HD

UMMS, Lundbeck enter research collaboration to develop targeted therapy for HD

Raptor completes enrollment in DR Cysteamine Phase 3 clinical trial in cystinosis

Raptor completes enrollment in DR Cysteamine Phase 3 clinical trial in cystinosis

MicroRNA-29 molecule makes brain cells resistant to programmed cell death

MicroRNA-29 molecule makes brain cells resistant to programmed cell death

Researchers report gene therapy strategy that improves Beta Thalassemia in mice model

Researchers report gene therapy strategy that improves Beta Thalassemia in mice model

Research suggests novel therapeutic approach for Huntington's Disease

Research suggests novel therapeutic approach for Huntington's Disease

Alnylam presents ALN-VSP Phase I trial results for liver cancer

Alnylam presents ALN-VSP Phase I trial results for liver cancer

VistaGen reports successful completion of AV-101 Phase 1 safety study for neuropathic pain

VistaGen reports successful completion of AV-101 Phase 1 safety study for neuropathic pain

Alnylam Pharmaceuticals progress in delivery and translation of RNAi therapeutics

Alnylam Pharmaceuticals progress in delivery and translation of RNAi therapeutics

FDA approves Neuralstem's IND to initiate NSI-189 Phase Ia safety trial in major depression

FDA approves Neuralstem's IND to initiate NSI-189 Phase Ia safety trial in major depression

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.